forearm blood flow
Conditions
Interventions
The single dose administration of ticagrelor (180 mg) or placebo
Sponsors
Universitair Medisch Centrum Sint Radboud
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: - Male sex - Age 18-40 years - Healthy - Written informed consent
Exclusion criteria
Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: - Smoking; - Hypertension (Blood pressure >140 mmHg and/or >90 mmHg - SBP/DBP-) - Diabetes Mellitus (fasting glucose > 7.0 mmol/L or random > 11.0 mmol/L); - History of any cardiovascular disease - History of chronic obstructive pulmonary disease (COPD) or asthma - Bleeding tendency - Concomitant use of medication - Renal dysfunction (MDRD < 60 ml/min) - Liver enzyme abnormalities (ALAT > twice upper limit of normality - Thrombocytopenia (<150*109/ml) - Second/third degree AV-block on electrocardiography
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Forearm blood flow response to the intrabrachial administration of adenosine and to 2 and 5 minutes of forearm ischemia (i.e. post-occlusive reactive hyperemia). | — |
Secondary
| Measure | Time frame |
|---|---|
| Forearm blood flow response to the intrabrachial administration of dipyridamole. Transport characteristics of the ENT transporter, determined ex vivo on isolated erythrocytes. | — |
Countries
Netherlands
Outcome results
None listed